Evaluation of the Assay for Serum Monoamine Oxidase – an Index of Hepatic Fibrosis by Gressner, A. M.
Gressner: Monoamine oxidase determination in serum
 92 j
J. Clin. Chem. Clin. Biodhem.
Vol. 18.1980, pp. 921-927
Evaluation of the Assay for Serum Monoamine Oxidase - an Index of Hepatic Fibrosis
By A. M. Gressner
Department of Clinical Chemistry and Pathobiochemistry of the Medical Faculty of the RWTH, Aachen, FRG
(Received Maich 18/June 13,1980)
Summary: At present, neither the diagnostic efficiency, the analytic reliability, nor the practicability of clinical chemi-
cal tests for estimation of the degree and/or activity of the fibrotic transformation of the chronically injured liver are
satisfactory. Among the various parameters proposed, the determination of the activity of monoamine oxidase (mo-
noaniine: O2 oxidoreductase, EC 1.4.3.4) in serum seems to be advantageous. To facilitate its routine use we studied
some important practical aspects of the new colorimetric assay for the activity of monoamine oxidase in serum.
The reaction procedes linearly with time for at least two hours and with enzyme concentrations up to 6 kU/1.
The buffer composition influences markedly the function of the enzyme; in Tris-HCl buffer (pH 7.2) at 37 ° C
the activity is 1.35 times higher than in phosphate buffer (pH 7.3) and the temperature correction factors are also
different for both buffer systems.
0.003 mol/1 of the lathyrogenic compound jS-aminopropionitrile inhibits the activity by about 50% whereas Cu2+ up
to 130 / does not affect enzyme function.
Intra- and interassay precision are characterized by a CV of 3.6 and 12%, respectively.
Hemolysis and hyperbilirubinemia do not interfere significantly with the determination but in hyperlipemic sera ele-
vated enzyme activities were noticed.
During storage of serum at room temperature the catalytic function decreases by about 30%/day.
Of the 26 quality control sera tested, only a few contained monoamine oxidase activity that was quantitatively (i.e.
similar'catalytic activity concentration) and qualitatively (i.e. comparable sensitivity to 0-aminppropionitrile and ratio
of activity in tris phosphate buffer) similar to that in human serum, and were therefore suitable for routine precision
control analysis.
Bewertung der Aktivitätsbestimmung der Monoaminoxidase im Serum - ein Parameter der Leberfibrose
Zusammenfassung: Gegenwärtig sind weder die diagnostische und analytische Zuverlässigkeit noch die Praktikabilität
klinisch-chemischer Testverfahren zur Erfassung des Grades und/oder der Aktivität der fibrotischen Transformation
der chronisch geschädigten Leber zufriedenstellend. Unter den verschiedenen vorgeschlagenen Kenngrößen erweist
sich die Aktivitätsbestimmung der Monoaminoxidase (Monoämino: O2 Oxidoreduktase, EC 1.4.3.4) im Serum als
vorteilhaft. Um ihre routinemäßige Anwendung zu erleichtern, untersuchten wir einige praktisch wichtige Aspekte
des neuen kolorimetrischen Bestimmungsverfahren der Aktivität der Monoämino Oxidase im Serum.
Die Reaktion verläuft bis zu einer katalytischen Konzentration des Enzyms von 6 kU/1 und für einen Zeitraum von
mindestens 2 Stunden linear.
Die Pufferkomppsition beeinflußt signifikant die Funktion des Enzyms; in Tris-HCl Puffer (pH 7,2) bei 37 °C ist die
Aktivität l,35fach höher als in Phosphat-Puffer (pH 7,3) und die temperaturkorrekturfaktoren sind ebenfalls ver-
schieden für beide Puffersysteme.
0,003 mol/1 der lathyrogenen Substanz /3-Aminöpropionitril hemmt die Aktivität um 50%, wohingegen Cu2+ bis zu
einer Konzentration von 130 jumol/l ohne Einfluß auf die Enzymaktivität ist.
Intra- und inter-serielle Präzision sind gekennzeichnet durch Variationskoeffizienten von 3,6 bzw 12%.
Hämolyse und Hyperbilirubinämie interferieren nicht mit der Bestimmung, in hyperlipidämischen Seren wurden je-
doch erhöhte Enzymaktivitäten festgestellt.
Während der Lagerung des Serums bei Raumtemperatur nimmt die katalytische Funktion um etwa 30%/Tag ab.
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Unter den 26 getesteten Kontrollseren enthalten nur wenige Monoaminoxidase-Aktivität, die quantitativ (d.h. ver-
gleichbare katalytische Konzentration) und qualitativ (d. h. vergleichbare Sensitivität gegenüber /3-Aminopropionitril
und ähnliches Aktivitätsverhältnis in Tris-/Phosphat-Puffer) der in menschlichen Seren vorhandenen entspricht. Mit-
hin sind nur wenige der kommerziell erhältlichen Kontrollseren für die Präzisionskpntrolle dieser Bestimmung geeig-
net.
Introduction
A common sequel of diverse forms of chronic hepatocel-
lular damage is the fibrotic change of the liver parenchy-
ma. The process, which is characterized by strong accu-
mulation of complex connective tissue proteins such as
various types of collagens (1,2) and proteoglycans (3,4),
is believed to involve stimulated synthesis rather than re-
duced breakdown of the intercellular macromolecules
(5-8). Despite its great clinical significance, the early di-
agnosis and therapeutic monitoring of hepatic fibropro-
liferation by biochemical means is presently hindered by
a limited supply of reliable and practicable clinical-che-
mical parameters (9-11). Of these, the determination of
the activity of monoamine oxidase (monoamine: 02 oxi-
doreductase, EC 1.4.3.4) in serum has been proposed as
a useful, supplementary diagnostic procedure for organ
fibrosis, in particular for active hepatic fibrosis (12—14).
Reported data (15,16) suggest the superiority of this en-
zyme to other currently available biochemical markers
of liver fibrosis, but direct and quantitative comparisons
have not yet been published. In order to make the de-
termination of the activity of monoamine oxidase in hu-
man serum suitable for standardized routine clinical use
and interlaboratory comparisons, it seemed necessary to
us to study some important properties of the enzyme
and of the recently developed, simplified, colorimetric
assay system (15).
Materials and Methods
Materials
l-[(4-aminomethyl-phenyl)azo]-2-naphthol hydrochloride was
purchased from Wako Pure Chemical Industries, Osaka, Japan;
0-aminopropionitrile fumarate (lot 108 C-0164) was from Sigma
Chemical Comp., München, FRG; phosphate buffer solution
(0.067 mol/1, pH 7.3 (20 °C), lot 203209 A) and the clearing
agent for turbid sera (Frigen) were from Behring Institute, Mar-
burg/Lahn, FRG; Sure-Sep II serum-plasma seperator was from
General Diagnostics, Morris Plains, USA; the sources of control
sera are listed in table 3. All other reagents were of analytical
grade.
Methods
Serum was prepared by centrifugation of venous blood which
had been allowed to clot for 1 hour at room temperature, using
the Sure-Sep II serum-plasma separator. Platelet-free plasma was
obtained by anticoagulation of 3 ml of blood in heparin-(Sarstedt,
N? 358) or ethylenediaminetetraacetate (EDTA)-(Sarstedt,
N? 328) containing test tubes and subsequent centrifugation,
using the Sure-Sep II serum-plasma separator.
In principle the activity of monoamine oxidase in sera was deter-
mined according to the method of Ono et al. (15). 0.5 ml serum
were incubated for one hour at 37 °C with 1.0 ml of l-[(4-ami-
nomethyl-phenyl)azo]-2-naphthol hydrochloride (0.5 mmoi/1)
and an equal volume of 0.1 mol/1 Tris-HCl buffer, pH 7.2 (20 °C).
The reaction was terminated by the addition of 0.1 ml perchloric
acid, and l-[(4-formylphenyl)azo]-2-naphthol formed during
incubation was extracted with cyclohexane and quantitated by
measuring its absorbance at 500 nm against cyclohexane. The cal-
culation of the enzyme activity was based on the reported molar
absorptivity of the reaction product (15). Modifications of this
general procedure are described in the legends of the appropriate
figures and tables.
General determinations
Hemoglobin was determined according to clinical-chemical stan-
dard procedures (17), total bilirubin (18) arid triglycerides (19)
were measured in a DuPont Automatic Clinical Analyzer and
GEMSAEC fast analyzer, respectively.
Results
The time-course of the monoamine oxidase assay in hu-
man serum and two quality control sera is shown in fi-
gure 1. The reaction proceeds linearly with time for at
least 2 hours, but marked differences were noted in the
activities of the enzyme depending on the buffer system
used. Monoamine oxidase in Seronorm (fig. la) was over
4 times more active in phosphate buffer than in Tris-
HCl, whereas the enzyme in human serum (fig. Ic) had
1.3 fold elevated activities in Tris HC1 buffer as com-
pared with phosphate buffer. On the other hand, enzyme
activity in Precipath (fig. Ib) was only slightly influenced
by the composition of the buffer during an incubation
time of about 80 min.
The serum containing the highest activity of monoamine
oxidase (Seronorm) was used to study the effect of en-
zyme concentration on the reaction rates at different
temperatures (fig. 2). The enzyme activity increased pro-
portionally at least up to 6 kU/1 which is about 15 times
above the activity in normal human serum. The activity
of the enzyme in Tris-HCl buffer at 37 °C was about
60% of that in phosphate buffer at 30 °C and increased
linearly with serum volume only up to 1.7 kU/1. At an
incubation temperature of 46 °C a sigmoidal activity
curve reaching a plateau at about 10 kU/1 was observed.
The temperature correction factors and temperature-de-
pendent tris/phosphate activity ratios of monoamine
oxidase in human serum and Seronorm are summarized
in table 1. In agreement with the information given in
figure 1 the data show clearly significant differences bet-
ween the enzymes in both sera, in particular a strong
and differential effect of incubation temperature on
the enzyme activity in Tris-HCl and phosphate buffer,
respectively.
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Fig. 1. The time-course of monoamine oxidase assay in control
sera and human serum.
The activities were determined in Seronorm (a), Precipath
(b) and in pooled normal human sera (c) either in the
presence of Tris-HCl (pH 7.2) (o—o) or phosphate
(pH 7.3) (χ—χ) buffer. The mean activities of 6 deter-
minations are given.
The adverse effects of the lathyrogenic compound j3-anii-
nopropioriitrile on monoamine oxidase activity in hu-
man serum and Seronorm are illustrated by figure 3. In
human serum 50% inhibition is reached at 0.003 mol/l,
complete inhibition at 0.150 mol/l. In the control serum,
however, the activity was found to be greatly stimulated
by the drug, the strongest increase (nearly 2.5 fold) was
observed at 0.080 mol/l j3-aminopropionitrile.
The results of intra- and inter-assay precision analyses
are shown in table 2. The accuracy of the test is difficult
to assess at present since no adequate control sera are ob-
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Fig. 2. The effect of enzyme concentration on the reaction rate,
depending on the incubation temperature and buffer
composition.
Increasing volumes of Seronorm were incubated with
Substrate for l h in the presence of either Tris-HCl buffer
at 37 °C (A—A), phosphate buffer at 37 °C (o—o),
phosphate buffer at 30 °C (Δ—Δ), or phosphate buffer
at 46 °C (·—·). Each value represents the mean activity
of 6 measurements.
10 50 ΘΟ 100 200
-Aminoprppionitrile [mmol/U
300
Fig. 3. The effect of 0-amino-propionitrile on the activity of
monoamine oxidase in normal human serum (·—·) and
in a quality control serum (Seronorm, o—o). Each
point represents the mean activity of 4 determinations,
which were performed in Tris-HCl buffer.
tainable. Applying the above mentioned criteria (tris/
phosphate activity ratio, effect of /J-aminopropionitrile)
a series of commercially available quality control sera
was analysed for monoamine oxidase to select the most
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Tab. 1. The effect of temperature on the buffer-dependent activity of monoamine oxidase in a quality control serum (Seronorm) and
normal human serum.
The samples were incubated for 1 hour at 20 °C, 30 °C and 37 °C either in the presence of a Tris-HCl (pH 7.2) or phosphate
buffer (pH 7.3) as described in fig. 1. The conversion factors and activity ratios were calculated from 4 independent measure-
ments.
Serum Buffer system Conversion factors
20° -> 30 °C 30° •37°C 20°-»37°C
Activity ratio (tris/phosphate)
20°C 30°C 37°C
Seronorm
Human serum
tris
phosphate
tris
phosphate
4.48
2.75
2.80
3.19
2.35
2.57
2.01
2.21
7.40
7.08
5.63
7.06
0.32
1.64
0.26
1.43
0.23
1.31
Tab. 2. Intra- and inter-assay precision of the determination of
monoamine oxidase activity in serum. The values are the
mean ± S.D. of 25 measurements.
Control serum Mono-
Hyland P
Precipath
Seronorm
am me
oxidase
(U/l)
91
412
1640
Intra-assay
S.D.
(U/l)
2.5
15
77
CV
(%)
2.7
3.6
4.7
Inter-assay
S.D.
(U/l)
13
54
157
CV
(%)
14
13
9.6
suitable ones for routine quality control (table 3). Among
the 26 sera tested 11 contained monoamine oxidase
quantitatively and qualitatively similar (albeit not iden-
tical) to that in sera of normal and liver-cirrhotic human
subjects (table 3). The remaining sera had enzyme activi-
ties definitely different from the human type and, hence,
are not favourable to precision control analyses of mono-
amine oxidase assay in normal and pathologic human
sera. It should be noted, that among the mixed type sera
originating mainly from animal and less from human
sources, Wellcomtrol 1,3, and 2 contained the highest
activities, but the enzyme in the last mentioned serum
was not influenced by the lathyrogenic drug.
The conditions of storage of the sample are of great im-
portance for a correct analysis (fig. 4). If the serum is
kept at room temperature the activity of monoamine
oxidase declines very rapidly, during the first 48 h by
30%/day. Best preservation of catalytic function in sera
is achieved either by deep-freezing, or by storage at
+4°C(fig.4).
Hemolysis and hyperbilirubinemia do not interfere sig-
nificantly with the assay of monoamine oxidase activity
in human serum (tab. 4). In hyperlipemic sera a signifi-
cant increase in the activity was noted which can be
avoided by delipid tion of the serum with Frigen based
agents prior to use (table 4). In no case, there was a need
to perform blank incubations, i.e. serum added after ter-
mination of the reaction.
S 1.00
0.75
S 0.50σ
•I 0.25
Ο 2 4 6 8
Time [dl
Fig. 4. The dependency of serum monoamine oxidase activity on
the conditions of storage.
Sera from 10 healthy persons were pooled and divided
into 3 equal portions, which were stored for various
times either at 22 °C (room temperature, α—G), at
4 °C (·—·) or in aliquots at - 20 °C (Δ-^-Δ). The
percentage of the remaining activity (mean value ± S.D.
of 6 determinations) is shown.
The activities of monoamine oxidase in serum, ethylene-
diaminetetraacetate (EDTA)- andheparin-anticoagulated,
platelet-free plasma of 8 healthy persons were 374 ± 99
U/l, 377 ± 93 U/l and 390 ± 100 U/l, respectively. Thus,
serum and plasma seem to be interchangeable for the de-
termination of monoamine oxidase.
The activities of monoamine oxidase in the sera of 178
healthy persons are listed iri table 5. They do not show
significant sex-related differences. In the age groups (18
to 55 years) tested no effect of age on enzyme activity
was noted (data not shown).
Increases iri the concentration of Cu2+ and Mg2"1" up to
130 μπιοΐ/ΐ and 20 mmol/1 incubation mixture, respecti-
vely, are without effect on the activity of monoamine
oxidase.
Discussion
Human blood serum contains a'soluble monoamine oxi-
dase that deaminates a variety of monoamines including
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Gressner: Monoamine oxidase determination in serum 925
n
 ί™**"0 (ρί? ?'2) a"d ph°sphate (P» 7·» buffer' «»Pectlvely, either in the absence or3.snd 5% concentration 0.08 mol/1). The mean activities of 4 determinations are listed, the CV
Control serum (producer)
Normal human serum
Cirrhotic human serum
Sera of human type
Flui Norm N (Behring)
Flui Norm P (Behring)
Precilip (Boehringer)
PKR (ASID)
Ortho Ria II (Ortho Diagnostics)
Ortho Ria I (Ortho Diagnostics)
Ortho Normal (Ortho Diagnostics)
Ortho Abnormal (Ortho Diagnostics)
Standard human plasma (Behring)
Precipath E (Boehringer)
Monitrol II-E (DADE)
Sera of mixed type
Bilirubin Control (DADE)
Q-Pak (Hyland Division)
Hyland N (Hyland Division)
Hyland P (Hyland Division)
Seroquant (Behring)
Kontrollogen L (Behring)
Monitrol I-E (DADE)
Precinorm U (Boehringer)
Normosic (ASID)
Validate A (G decke)
Serononm (Nyegaard)
WeUcomtrol 2 (Wellcome)
Pathonorm L (Nyegaard)
Wellcomtrol 1 OyeUcome)
WeUcomtrol 3 (WeUcome)
Lot No.
—
134 B
144 H
661
H 1245-1
2 S 507
3 S 407
5 R 215
9S317
502533 B
833
PTD-60 A
BIC-940
1838UOO2AAD
N 05 A
P11E
624 103
3106 K
LTD- 147 B
839
414 B
0641117
147
K 7489
12
K 7486
K 7490
Monoamine
(U/l)
Tris
284
902
102
102
118
139
167
176
203
240
392
539
720
32
75
100
103
109
120
142
153
201
475
1071
2710
4488
5307
7242
oxidase
Phosphate
215
600
73
82
80
96
132
143
172
198
345
450
599
17
61
85
109
122
108
134
297
247
458
4596
5150
3107
9442
9045
Ratio
of activity
Tris/
Phosphate
1.32
1.50
.40
.24
.48
.45
.27
.23
1.18
1.21
1.14
1.20
1.20
1.88
1.23
1.18
0.94
0.89
1.11
1.06
0.52
0.81
1.04
0.23
0.53
1.44
0.56
0.80
Inhibition (
Tris
-89
-92
- 90S\J
- 90
-82
- 87
- 88
- 82
-86
-87
-78
-74
-85
-53
-63
-61
-62
-76
-81
-77
-58
-82
-83
+ 103
0
-49
-52
-70
W
Phosphate
-91
-90
- 86ou
- 88oo
-75
-66
- 59
-67
-76
-61
- 75
-65
-77
+ 259
-57
-53
-67
-85
-66
-75
-77
-68
-72
-15
0
-28
-65
-71
benzylamine, tyramine, tryptamine, dopamine and phe-
nylethylamine (21, 22). Neither the physiological role
nor the origin of the circulating form of monoamine oxi-
dase are known. In its substrate specifity it resembles the
type B (23—25) mitochondria! outer membrane monoa-
mine oxidase, but the inhibition by lathyrogens (26, 27),
such as j3-aminopropionitrile, and electrophoretic mobili-
ty clearly indicate marked differences between these two
enzymes (12, 28). As a further criterion we showed that
the serum enzyme is insensitive to Cu24", whereas the
liver mitochondrial enzyme was reported to be strongly
inactivated (29).
Previous studies have demonstrated elevated enzyme ac-
tivities under several pathological conditions, especially
iri progressive hepatic fibrosis (12—16, 30-32). The
latter observation established the diagnostic significance
of the enzyme and suggested that it might catalyze the
initial step of collagen cross-linking in the liver (12, 31,
32). However, purified amine oxidase does not utilize
collagen substrates (33) and is antigenically different
from liver lysyl oxidase (34), which also increases in the
serum of liver-fibrotic rats (35). Thus, the role of serum
monoamine oxidase in hepatic connective tissue metabol-
ism remains obscure.
Obviously serum monoamine oxidase is composed of
multiple, biologically undefined forms (15) of which the
quantitative relation might change in certain pathologi-
cal states (32). Modifications of the assay conditions can
therefore selectively affect the activity pattern of the iso-
enzymes of monoamine oxidase in health and disease. We
have shown that there is an increase in the activity of the
human serum enzyme if the phosphate buffer originally
used by Me Ewen & Cohen (21) is replaced by Tris-
HQ buffer, and, furthermore, that the temperature cor-
rection factors are different for the two buffer systems.
According to our results, sera from cirrhotic patients
contain monoamine oxidase that is qualitatively similar
to that in normal serum, but differences in the isoenzy-
me composition have been described (32, 36, 37). It
should be emphasized that quality control of the assay
J. Clin. Chern, Clin. Biochem. / Vol. 18, 1980 / No. 12
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Tab. 4. Interferences of hemolysis, hyperlipemia, and bili-
rubinemia with the determination of monoamine oxid-
ase activity in human serum. Increasing volumes of con-
centrated stock solutions were added to normal human
sera to get final concentrations of hemoglobin, tri-
glycerides, and bilirubin, respectively, as listed. A solu-
tion of 4.22 mmol/1 hemoglobin was obtained by
hemolysis of washed erythrocytes in distilled water by
repeated freezing and thawing. A triglyceride-
(12.8 mmol/1) and cholesterol- (9.7 mmol/1) rich solu-
tion was prepared from pooled hyperlipemic human
sera. The sera were centrifuged (8 h, 4 °C, 30000£)
and the lipid-rich supernatant, which was free of rnpno-
amine oxidase activity, was aspirated. Bilirubin Control
(DADE, lot BIC-941) was dissolved in water to get a
solution of 513 μηιοΐ/ΐ bilirubin. Some of the sera were
delipidized with Frigen (20). Blank incubations were
performed by adding the sera after termination of the
reaction. Absorptivity of blank and sample incubations
were measured against cyclohexane. The mean activities
± S.D. of 6 determinations are given.
c·
AAblank AAsampie Monoamine
oxidase
(U/l)
x ± S.D.
Hemoglobin (mmol/1)
0 0.003 0.068 335 10
0.422 0.003 0.065 320 12
0.844 0.004 0.063 310 24
Triglycerides (mmol/1)
1.49 0.001 0.099 483 22
4.06 0.001 0.122 597 34
4.06 (treated with Frigen) 0.001 0.099 483 19
6.62 0.002 0.125 610 35
Bilirubin (μιηοΐ/ΐ)
9.2
60.5
214.4
0.001
0.000
0.001
0.066
0.074
0.073
325
363
360
17
21
10
Tab. 5. Reference ranges for the activity of serum monoamine
oxidase. The enzyme was'determined in the sera of 178
biochemically and clinically healthy persons ranging
from 18 to 55 years according to the standard assay
procedure using Tris-HCl buffer.
Monoamine oxidase activity
(U/l)
-2s mean +2s
Men
Women
109
69
148
106
380
390
612
674
conditions is comlicated by the fact that only few com-
mercially available control sera contain monoamine oxi-
dase approximating to the human serum type. The vari-
able degrees of the inhibition (in Seronorm even strong
activation!) by /J-aminopropionitrile suggest the presence
of variable amounts of type B tissue monoamine oxidase
in the sera, which might also explain their different Tris/
phosphate activity ratios.
Although the within-run precision is satisfactory, the
disadvantages (large sample volumes, time-consuming
and manual procedure, relative insensitivily) of even the
improved colorimetric mothod (15) hinder its frequent
application in the routine diagnosis of hepatic fibropro-
liferation. To overcome these drawbacks we are current-
ly developing a sensitive arid rapid kinetic procedure for
the assay of monoamine oxidase activity in serum which
can be fully mechanized.
Alternatively, immunologic quantitation seems favour-
able since it bypasses the marked instability of the en-
zyme activity at room temperature.
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